Clinical Trials
52 trialsAlemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
M.D. Anderson Cancer Center
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Eastern Cooperative Oncology Group
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Northwestern University
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
University of California, San Diego
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
ADVL
Baylor College of Medicine
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
ALBUM
University of Arizona
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
University of California, San Francisco
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
OHSU Knight Cancer Institute
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
REGALE
Baylor College of Medicine
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona
Campath Maintenance in Chronic Lymphocytic Leukemia
Northwell Health
Alemtuzumab + Rituximab Consolidation in CLL
M.D. Anderson Cancer Center
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
University of Chicago
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Case Comprehensive Cancer Center
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
National Cancer Institute (NCI)
LLC0405
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
National Cancer Institute (NCI)
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
French Innovative Leukemia Organisation
CFAR Study in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
MPDMDSBMT
Baylor College of Medicine
Alemtuzumab and Pentostatin In T-cell Neoplasms
M.D. Anderson Cancer Center
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center